Abstract
Pan proviral insertion site of Moloney murine leukemia (PIM) 1, 2, and 3 kinase inhibitors have recently begun to be tested in humans to assess whether pan PIM kinase inhibition may provide benefit to cancer patients. Herein, the synthesis, in vitro activity, in vivo activity in an acute myeloid leukemia xenograft model, and preclinical profile of the potent and selective pan PIM kinase inhibitor compound 8 (PIM447) are described. Starting from the reported aminopiperidyl pan PIM kinase inhibitor compound 3, a strategy to improve the microsomal stability was pursued resulting in the identification of potent aminocyclohexyl pan PIM inhibitors with high metabolic stability. From this aminocyclohexyl series, compound 8 entered the clinic in 2012 in multiple myeloma patients and is currently in several phase 1 trials of cancer patients with hematological malignancies.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amides / chemical synthesis
-
Amides / chemistry
-
Amides / therapeutic use
-
Animals
-
Cell Line, Tumor
-
Halogenation
-
Humans
-
Leukemia, Myeloid, Acute / drug therapy*
-
Leukemia, Myeloid, Acute / metabolism
-
Mice
-
Models, Molecular
-
Picolinic Acids / chemical synthesis
-
Picolinic Acids / chemistry
-
Picolinic Acids / therapeutic use*
-
Protein Kinase Inhibitors / chemical synthesis
-
Protein Kinase Inhibitors / chemistry
-
Protein Kinase Inhibitors / therapeutic use*
-
Protein Serine-Threonine Kinases / antagonists & inhibitors*
-
Protein Serine-Threonine Kinases / metabolism
-
Proto-Oncogene Proteins / antagonists & inhibitors*
-
Proto-Oncogene Proteins / metabolism
-
Proto-Oncogene Proteins c-pim-1 / antagonists & inhibitors*
-
Proto-Oncogene Proteins c-pim-1 / metabolism
Substances
-
Amides
-
Picolinic Acids
-
Pim2 protein, mouse
-
Protein Kinase Inhibitors
-
Proto-Oncogene Proteins
-
Pim1 protein, mouse
-
Pim3 protein, mouse
-
Protein Serine-Threonine Kinases
-
Proto-Oncogene Proteins c-pim-1
-
picolinamide